Dextromethorphan
(+)-3-methoxy-17-methylmorphinan
Viewing r1 — Apr 24, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
DXM (dextromethorphan) is a synthetic dissociative of the morphinan class. It is the non-opioid mirror image of levomethorphan, retaining cough-suppressing activity without meaningful opioid effects.[1] It blocks glutamate signaling in the brain[2] and inhibits serotonin reuptake,[3] producing its characteristic dissociation and euphoria.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, PCP, nitrous oxide +1 moreketamine, PCP, nitrous oxide, memantine show less
DXM was first tested as a cough suppressant in 1954 and FDA-approved in 1958 as the first non-opioid antitussive.[1] Recreational misuse was documented by the 1960s, and a surge in teenage abuse prompted over 20 US states to restrict sales to adults.[4] It is now also an ingredient in two FDA-approved psychiatric medications — one for a neurological condition that causes uncontrollable emotional outbursts,[5] and one for depression.[6]
Subjective effects include dissociation, euphoria, time alteration, derealization, and vivid hallucinations at higher amounts. The experience escalates through dose-dependent stages — from mild stimulation to a profound mind-body separation — with a warmer, more euphoric character than ketamine. Nausea, dizziness, confusion, and motor impairment are common unwanted effects.
Both physical and psychological dependence develop with chronic use,[7][4] and no human lethal dose has been established. The primary acute danger is combining DXM with serotonergic drugs — MAOIs in particular can trigger a life-threatening overheating and seizure response;[8] genetic variation in liver metabolism means identical doses affect people very differently.[9] Decades of clinical use and multiple FDA approvals provide a strong evidence base, but no controlled studies of recreational-dose effects have been published.
History[edit]
Discovery
The morphinan chemical family was explored at Hoffmann-La Roche in the mid-1940s, with a US patent granted in 1950.[10] The two mirror-image forms of methorphan had completely different effects: the levorotatory form was a potent opioid; the dextrorotatory form suppressed coughs without opioid activity. DXM was tested as an antitussive in 1954 — partly funded by the US Navy and CIA — and FDA-approved in 1958 as the first non-narcotic cough suppressant.[1]
Clinical adoption and misuse
DXM rapidly displaced codeine as the dominant over-the-counter cough suppressant worldwide.[1] Recreational misuse appeared in medical literature by the 1960s and escalated sharply among teenagers by the 2000s.[4] Over 20 US states have since passed laws restricting DXM sales to individuals 18 or older.[11]
Therapeutic renaissance
DXM's multiple receptor targets — initially a pharmacological inconvenience — became therapeutically useful once its pharmacology was understood. The FDA approved Nuedexta in 2010 for pseudobulbar affect, a neurological condition causing uncontrollable laughing or crying.[5] In 2022, Auvelity was approved for major depression in adults.[6]
The name dextromethorphan combines Latin dexter (right) — referring to the molecule's dextrorotatory optical rotation — with methorphan, the morphinan-class parent compound. The abbreviation DXM is universal in both clinical and recreational contexts. In recreational culture, DXM's dose-dependent effects are traditionally organized into four plateaus, a framework originating in online user communities in the late 1990s that maps escalating dissociative intensity from mild stimulation to complete hallucinogenic dissociation.
Chemistry[edit]
Structural class
DXM belongs to the morphinan chemical class — the same family as codeine and morphine, though DXM has no meaningful opioid activity. Its molecular formula is C₁₈H₂₅NO.
The liver enzyme CYP2D6 converts DXM into an active metabolite called dextrorphan, which binds the same brain receptors with roughly eightfold greater potency and is largely responsible for the dissociative effects at higher doses.[12]
Pharmacology[edit]
Mechanism of action
DXM blocks glutamate signaling in the brain by occupying a channel inside NMDA receptors — the same channel targeted by ketamine and PCP.[2] Its liver metabolite dextrorphan does this with roughly eightfold greater potency,[2] and dextrorphan accumulation at higher doses drives the characteristic disconnection from reality.[7]
DXM also activates sigma-1 receptors,[2] which are involved in emotional regulation and likely contribute to its antidepressant effects. It inhibits serotonin reuptake,[3] which adds a warm, euphoric quality to the experience — and is the reason combining DXM with serotonergic drugs is dangerous.
Pharmacokinetics
The liver enzyme CYP2D6 converts DXM to dextrorphan.[12] In the roughly 90% of people who metabolize DXM quickly, blood levels stay low and the drug clears fast; in the roughly 8–10% who metabolize it slowly, the same dose produces far higher blood levels and lasts far longer.[9] Drugs that block CYP2D6 produce the same effect pharmacologically — bupropion raises DXM exposure more than 100-fold,[13] and quinidine extends DXM's half-life from 2–3 hours to over 16 hours.[9]
Neuroscience[edit]
Where it acts
DXM's dissociative effects arise from blocking NMDA receptors in the cortex and thalamus.[2] These receptors maintain the coherent neural activity that underlies waking consciousness; blocking them disrupts the brain's sense of self and spatial reality, producing depersonalization and derealization. The blockade is use-dependent — circuits that are more active get disrupted more.[14]
Why it matters
DXM also activates sigma-1 receptors[2] in brain areas involved in emotion and memory. This increases levels of BDNF — a protein that promotes neuron growth and survival[15] — which is believed to drive the rapid antidepressant effects seen with NMDA antagonists like ketamine. The FDA approval of DXM/bupropion for depression[16] validates this mechanism clinically.
Poor metabolizers accumulate mostly parent DXM (sigma-1 and serotonin-dominant) while extensive metabolizers produce mostly dextrorphan (NMDA-dominant) — these populations may experience qualitatively different states from identical doses, but no controlled comparison exists.
Subjective Effects[edit]
DXM's character is shaped by two unusual variables: how much was taken, and how the individual's liver processes it. Genetic variation in a liver enzyme means two people taking the same dose may experience qualitatively different states. The experience escalates through distinct stages as dose increases, from mild stimulation to complete disconnection from the self.
Compared to ketamine, DXM's dissociation arrives more slowly and lasts much longer. Where ketamine can feel cold and anesthetic at dissociative depths, DXM tends toward warmth and euphoria — reflecting its additional activity on serotonin pathways layered onto the core glutamate blockade.
Effect Grid
At common doses (200–400 mg oral DXM HBr), the dissociative character of the experience becomes unmistakable. Euphoria intensifies, often accompanied by a sense of bodily dissociation — the feeling of separation between mind and physical form. Music distortion and enhancement become prominent. Visual distortions emerge: drifting of surfaces, closed-eye visuals with geometric or abstract imagery, and altered color perception. Time distortion is marked, with subjective time typically feeling stretched. Thought disorganization increases, with dream-like or surreal cognitive patterns.
Physically, pronounced nystagmus, ataxia, and motor incoordination are typical. Nausea and vomiting occur in a significant minority. Tachycardia and mild hypertension are common. Speech becomes slurred. Sleep is impossible for 6–8 hours. Functional impairment is substantial — driving or operating machinery is unsafe.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Perspective distortion · Tracers · Visual haze / noise · Visual drifting · Auditory distortion · Music enhancement · Proprioceptive distortion · After-images · Visual morphing · Touch suppression · Auditory enhancement · Color enhancement · Auditory misinterpretation · Brightness alteration · Holotropic state · Sensory deprivation · Sleep-transition hallucinations · Visual magnification · Dreaming enhancement · Synesthesia · Color alteration · Geometry · Peripheral vision distortion · Sound sensitivity · Visual breathing · Auditory suppression · Environmental patterning · Light sensitivity · Tinnitus · Touch enhancement · Visual diffraction · Visual melting · Visual processing acceleration · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Visual scenery slicing · External hallucinations · Object transformations · Visual recursion · Gustatory hallucination
Auditory distortion · Music enhancement · Proprioceptive distortion · After-images · Visual morphing · Touch suppression · Auditory enhancement · Color enhancement · Auditory misinterpretation · Brightness alteration · Holotropic state · Sensory deprivation · Sleep-transition hallucinations · Visual magnification · Dreaming enhancement · Synesthesia · Color alteration · Geometry · Peripheral vision distortion · Sound sensitivity · Visual breathing · Auditory suppression · Environmental patterning · Light sensitivity · Tinnitus · Touch enhancement · Visual diffraction · Visual melting · Visual processing acceleration · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Visual scenery slicing · External hallucinations · Object transformations · Visual recursion · Gustatory hallucination
Body high · Body schema distortion · Nausea · Pain suppression · Pupil dilation · Stimulation · Bodily lightness · Spontaneous body sensations · Involuntary body movements · Muscle relaxation · Appetite suppression · Bodily heaviness · Laughter fits · Physical fatigue · Tingling / electric sensations · Vibrations / buzzing · Sexual arousal suppression · Excessive sweating · Dry mouth · Heart rate perception changes · Insomnia · Tactile euphoria · Vomiting · Sexual arousal enhancement · Abnormal heartbeat · Respiratory depression · Restlessness · Trembling · Wakefulness · Increased urination · Bodily dissociation · Tactile hallucination
Pain suppression · Pupil dilation · Stimulation · Bodily lightness · Spontaneous body sensations · Involuntary body movements · Muscle relaxation · Appetite suppression · Bodily heaviness · Laughter fits · Physical fatigue · Tingling / electric sensations · Vibrations / buzzing · Sexual arousal suppression · Excessive sweating · Dry mouth · Heart rate perception changes · Insomnia · Tactile euphoria · Vomiting · Sexual arousal enhancement · Respiratory depression · Restlessness · Trembling · Wakefulness · Increased urination · Bodily dissociation · Tactile hallucination
Memory suppression · Focus suppression · Information processing suppression · Thought disorganization · Cognitive fatigue · Immersion enhancement · Motivation suppression · Cognitive euphoria · Thought deceleration · Pattern recognition suppression · Humor enhancement · Novelty enhancement · Aesthetic enhancement · Introspection enhancement · Memory fragmentation · Conceptual thinking · Compulsive redosing urge · Language suppression · Openness enhancement · Thought connectivity · Thought loops · Creativity enhancement · Cognitive dysphoria · Delusions of sobriety · Amnesia · Delusions · Delirium
Thought disorganization · Cognitive fatigue · Immersion enhancement · Motivation suppression · Cognitive euphoria · Thought deceleration · Pattern recognition suppression · Humor enhancement · Novelty enhancement · Aesthetic enhancement · Introspection enhancement · Memory fragmentation · Conceptual thinking · Language suppression · Openness enhancement · Thought connectivity · Thought loops · Creativity enhancement · Cognitive dysphoria · Delusions of sobriety · Amnesia · Delusions · Delirium
Anxiety · Emotional lability · Emotional suppression · Dysphoria · Simultaneous emotions
Simultaneous emotions
Communication suppression · Sociability suppression · Social disconnection · Automaticity · Emotional susceptibility · Ego inflation · Craving · Flow state · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Emotional susceptibility · Ego inflation · Craving · Flow state · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Near-death experience · Non-dual awareness · Voidness · Cessation
Timeline
First alerts emerge as mild warmth, slight mood shift, or faint nausea. The wide onset window (30–120 minutes) reflects CYP2D6-dependent absorption and first-pass metabolism variability.
Effects build steadily: mood elevation, growing body dissociation, and emerging perceptual shifts. Nausea peaks during this phase for many users. A sense of physical heaviness or floating develops.
Maximum dissociative intensity. Euphoria, depersonalization, perceptual distortions, and thought disorganization reach their zenith. Music distortion and enhancement are most pronounced.
Dissociative effects sustain at reduced intensity. Cognitive cloudiness and motor impairment persist. The dreamy, floating quality of the experience stabilizes.
Gradual return of normal body awareness and environmental connection. Cognitive fog lifts slowly. Mild residual euphoria or emotional flatness.
Residual cognitive cloudiness, mild mood changes, and subtle dissociative aftereffects may persist for 4–24 hours. Duration is strongly CYP2D6-dependent — poor metabolizers experience substantially longer aftereffects.
⚠ Do not drive or operate machinery until at least 24 hours after ingestion, or longer if residual impairment is felt.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · PCP · nitrous oxide
Toxicity
No human lethal dose has been established for DXM. The margin between a therapeutic antitussive dose (15–30 mg) and serious toxicity is relatively wide, though it narrows substantially with concurrent medications or poor metabolizer status.
Toxicity thresholds
Evidence-based guidelines establish the following clinical thresholds for DXM ingestion[17]:
- Above 4 mg/kg: Up to 64% of people experience psychoactive effects
- 5–7.5 mg/kg: Increased monitoring recommended
- Above 7.5 mg/kg: Emergency department referral recommended
Common effects at doses above 4 mg/kg include euphoria, nausea and vomiting, involuntary eye movement, and dizziness.[8]
Severe overdose
At high doses, DXM toxicity combines dissociative, serotonergic, and sedative features.[8] Serotonin syndrome — a life-threatening overheating and seizure response — is the most dangerous acute risk, especially when combined with serotonergic medications. Other severe outcomes include respiratory depression (especially with sedative combinations), dangerous overheating, and muscle breakdown from prolonged seizures.
Published cases document survival from massive ingestions — including 5,600 mg causing prolonged seizures with full recovery by day 9,[18] and over 100 tablets causing shock and convulsions requiring intensive care[19] — though these required aggressive hospital intervention.
CYP2D6 and toxicity
Poor metabolizers and people taking CYP2D6-inhibiting medications (paroxetine, fluoxetine, bupropion, quinidine) accumulate far higher DXM blood levels from the same dose. A dose tolerated by most people may produce life-threatening toxicity in a poor metabolizer.
Psychological risks
High doses can produce paranoia, hallucinations, severe agitation, and disorientation.[8] Chronic misuse is associated with sustained psychosis, depression, and cognitive impairment.[7] The risk is amplified in people with pre-existing psychiatric conditions, particularly psychotic spectrum disorders.
Tolerance & dependence
Tolerance develops with repeated use. Cross-tolerance occurs with other NMDA antagonist dissociatives — ketamine and PCP. Community-reported timelines — buildup with prolonged use, roughly 5-day half-life, approximately 1.5-week full reset — have not been validated in controlled studies.citation needed
Physical and psychological dependence with chronic DXM use is documented, with withdrawal syndromes consistent with NMDA antagonist discontinuation.[7][4] In animal models, DXM also modulates opioid and nicotine dependence behaviors.[20]
Drug interactions
DXM's multiple receptor targets create interaction risks through both additive drug effects and altered metabolism.
Serotonergic interactions
MAOIs are an absolute contraindication — combining them with DXM causes catastrophic serotonin accumulation with documented fatalities, requiring a minimum 14-day washout.[8][17] SSRIs and SNRIs carry significant serotonin syndrome risk, compounded when the SSRI also inhibits CYP2D6 — paroxetine and fluoxetine create both pharmacological and metabolic amplification.[7][21] Tramadol and MDMA also pose serious serotonin syndrome risk.
CNS depressant interactions
Alcohol, GHB/GBL, benzodiazepines, and opioids produce additive sedation and respiratory depression with DXM. Dissociative impairment of protective reflexes also increases aspiration risk during sedation.
Pharmacokinetic interactions
Strong CYP2D6 inhibitors dramatically increase DXM blood levels. Bupropion raises DXM exposure more than 100-fold;[13] quinidine extends DXM's half-life from 2–3 hours to over 16 hours.[9] These interactions are therapeutically exploited in approved formulations but are dangerous at recreational doses.
Dissociative synergy
PCP acts at the same brain receptor site as DXM. Combined use produces extreme, unpredictable dissociation with additive effects throughout the central nervous system.
Drug testing note
DXM is not detected by standard opioid drug screens. Some immunoassay panels may misidentify it as PCP due to structural similarities.[1]
Contraindications
- MAOI use (absolute): Any current or recent (within 14 days) MAOI use is an absolute contraindication due to fatal serotonin syndrome risk.[8]
- Serotonergic medication use (relative to absolute): SSRIs, SNRIs, tramadol, and other serotonergic drugs substantially increase serotonin syndrome risk. Agents that also inhibit CYP2D6 (paroxetine, fluoxetine) create compounded risk.
- CYP2D6 poor metabolizer status (relative): Known poor metabolizers face dramatically elevated plasma DXM levels at any dose, increasing all adverse effects.
- Hepatic impairment (relative): Reduced liver metabolism may increase DXM accumulation, though substance-specific data are limited.citation needed
- Psychotic spectrum disorders (relative): NMDA antagonism can precipitate or worsen psychotic symptoms, particularly at high doses.[7]
- Respiratory compromise (relative): High-dose DXM can depress breathing, particularly combined with other sedatives.[8]
Harm Reduction[edit]
Forms & Identification
DXM is available as syrups, capsules, tablets, and powder-filled gelcaps. The critical concern is not DXM itself but the other active ingredients in combination products. Many cough and cold formulations contain acetaminophen (paracetamol), which causes severe liver damage at quantities consumed when DXM is taken at supratherapeutic doses.
Only products listing DXM as the sole active ingredient should be considered if DXM is being used outside its labeled indication. This is the single most important harm reduction measure — more emergency presentations involve co-formulated ingredients than DXM itself.
Guidelines
- Verify the product contains DXM as the sole active ingredient — no acetaminophen, no antihistamines, no guaifenesin
- Start with a low dose and wait at least 2 hours before considering redosing — onset is slow and unpredictable
- CYP2D6 metabolizer status dramatically affects intensity; individuals who have unusually strong reactions to normal doses may be poor metabolizers
- Have a sober companion present, particularly at doses above mild stimulant effects
- Keep the environment physically safe — DXM impairs coordination and spatial awareness at moderate-to-high doses
- Do not drive or operate machinery for the full duration plus recovery time
- Stay hydrated with small sips; do not force fluids during nausea
Set & Setting
DXM's long duration and dose-dependent escalation into deep dissociation make environment and mental preparation especially important. A safe, comfortable indoor space with a sober, trusted companion is strongly advisable — particularly at higher doses, where mobility and spatial awareness are significantly impaired.
Arranging the space to minimize fall hazards and keeping water accessible is practical preparation for a substance that frequently causes nausea and overheating. The extended timeline means planning for an entire day or evening without obligations.
Aftercare & integration. DXM's extended duration means aftereffects can persist well into the following day. Low-demand rest, adequate hydration, and light nutrition support recovery. Cognitive fogginess, emotional flatness, or mild dissociative feelings for 24–48 hours after use are commonly reported and typically resolve without intervention.
For those who experienced intense or unsettling dissociation, grounding techniques help re-establish embodied presence — physical contact with textured objects, cold water on the face, focused breathing, naming objects in the immediate environment. Talking through the experience with a trusted person can aid processing, particularly if the experience involved disturbing content.
Recovery & Support
Chronic DXM use can produce psychological and physical dependence with a recognized withdrawal. Those who find themselves using DXM compulsively, needing escalating doses for the same effect, or experiencing anxiety, insomnia, or low mood when stopping should consider professional support.
SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals in the United States. Online peer support communities exist, though professional assessment is recommended for anyone experiencing dependence symptoms.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Mild nausea, dizziness, and confusion at low doses are common and generally self-limiting. Seek immediate help for: seizures, loss of consciousness or inability to be roused, extremely high body temperature (skin hot to the touch), rigid or jerking muscles (possible serotonin syndrome), severely slowed or stopped breathing, or chest pain.
Immediate steps:
- 1. Call emergency services if the person is unconscious, seizing, or showing signs of serotonin syndrome
- 2. Place an unconscious but breathing person on their side (recovery position) to prevent choking
- 3. Do not induce vomiting
- 4. Do not leave the person alone
- 5. Remove excess clothing if overheating; cool with damp cloths if body temperature is dangerously high
- 6. Monitor breathing continuously until help arrives
What to tell the dispatcher: Name the substance (dextromethorphan/DXM), estimated amount, time of ingestion, any other substances or medications involved, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Dextromethorphan occupies an unusual regulatory position: widely available as an OTC medication in most jurisdictions and federally unscheduled in the United States, but subject to targeted age-restriction legislation due to its documented recreational misuse potential.
In the United States, DXM is not listed under the Controlled Substances Act and carries no federal age restriction for purchase.[11] Over 20 individual states have enacted laws restricting sale of DXM-containing products to individuals under 18, with some states requiring ID verification for purchasers appearing under 25–27.[11]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled | Not listed in CSA; OTC without federal age restriction[11] |
| United States (20+ states) | Age-restricted OTC | Sale restricted to individuals 18+; ID verification required[11] |
| United Kingdom | General sale | Available OTC without restriction[22] |
| Canada | OTC | Available without prescription[22] |
| Australia | Schedule 2 (Pharmacy Medicine) | Restricted OTC availability under TGA scheduling[22] |
| Russia | Schedule III controlled substance | Controlled; not available OTC[22] |
| Sweden | Unavailable | Not marketed[22] |
| Norway | Unavailable | Not marketed[22] |
| Denmark | Prescription only | Available by prescription[22] |
references
- [1]
- [2]
- [3] ^abWerling LL, Keller A, Frank JG, Nuwayhid SJ (2007) A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder — Experimental Neurology PMID:17689532
- [4] ^abcdMutschler J, Koopmann A, Grosshans M, Hermann D, Mann K, Kiefer F (2010) Dextromethorphan withdrawal and dependence syndrome — Deutsches Arzteblatt International doi:10.3238/arztebl.2010.0537
- [5] ^abMuneer MA, Tariq I, Zulfiqar E, et al. (2026) Efficacy and safety of dextromethorphan/quinidine in treating pseudobulbar affect: A systematic review and network meta-analysis — Neurological Sciences doi:10.1007/s10072-025-08640-7
- [6] ^abMcIntyre RS, Jain R (2024) Glutamatergic Modulators for Major Depression from Theory to Clinical Use — CNS Drugs doi:10.1007/s40263-024-01114-y